Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Blood (2025) 146 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2025-2755

Published: 2025

Journal Articles

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

Patrizia Porazzi, Martina Pucillo, Anushka Anant Padmanabhan, Siena Nason, Zhixuan Zheng, Luca Paruzzo, Matthew Ho, Peter Michener, Federico Stella, Antonio Imparato, Sandra Susanibar-Adaniya, Alfred Garfall, Joseph Fraietta, Marco Ruella

Blood (2025) 146 (Supplement 1): 2160.

https://doi.org/10.1182/blood-2025-2160

Published: 2025

Journal Articles

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

Melody Tan, Josephine Giles, Patrizia Porazzi, Leonel Torres, Luca Paruzzo, Alberto Carturan, Wumesh KC, Yunlin Zhang, Raymone Pajarillo, E. John Wherry, Marco Ruella

Blood (2025) 146 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2025-4097

Published: 2025

Journal Articles

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Blood (2025) 146 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2025-4120

Published: 2025

Journal Articles

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Blood (2025) 146 (Supplement 1): 808.

https://doi.org/10.1182/blood-2025-808

Published: 2025

Journal Articles

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Blood (2025) 146 (Supplement 1): 804.

https://doi.org/10.1182/blood-2025-804

Published: 2025

Journal Articles

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Blood (2025) 146 (Supplement 1): 699.

https://doi.org/10.1182/blood-2025-699

Published: 2025

Journal Articles

Trends in muscle and fat metrics and their association with outcomes following CAR T-cell therapy in older adults with non Hodgkin lymphoma.

Gabriel Aleixo, Luca Paruzzo, Rakesh Sharma, Walter Witchey, Marco Ruella, Daniel Landsburg, Stefan Barta, Jakub Svoboda, Stephen Schuster, Elise Chong, Pashna Munshi, Sandra Susanibar, Sunita Dwivedy Nasta

Blood (2025) 146 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2025-3553

Published: 2025

Journal Articles

Humanized PDX models reveal Lymphoma–Host interactions and enhanced T-cell therapies via epigenetic modulation

Blood (2025) 146 (Supplement 1): 350.

https://doi.org/10.1182/blood-2025-350

Published: 2025

Journal Articles

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Blood (2025) 146 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2025-4543

Published: 2025

Journal Articles

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

Heta Patel, Luca Paruzzo, Oxana Megherea, Matthew Ho, Thomas Luo, Dan Vogl, Shivani Kapur, Adam Waxman, Federico Stella, Alberto Carturan, Martina Pucillo, Antonio Imparato, Edward Stadtmauer, Alfred Garfall, Adam Cohen, Marco Ruella, Sandra Susanibar-Adaniya

Blood (2025) 146 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2025-3995

Published: 2025

Journal Articles

Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy

Blood (2025) 146 (Supplement 1): 5905.

https://doi.org/10.1182/blood-2025-5905

Published: 2025

Journal Articles

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, Bhoomi Madhu, Luca Paruzzo, Kecheng Han, Alexander Shestov, Chaoting Zhou, Jason Lin, Alberto Carturan, Patrizia Porazzi, Elise Chong, Stephen Schuster, Michael Milone, Christoph Thaiss, Maayan Levy, Marco Ruella

Blood (2025) 146 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2025-5903

Published: 2025

Journal Articles

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Blood (2025) 146 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2025-5945

Published: 2025

Journal Articles

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Blood (2025) 146 (Supplement 1): 5337.

https://doi.org/10.1182/blood-2025-5337

Published: 2025

Journal Articles

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Blood (2025) 146 (Supplement 1): 5501.

https://doi.org/10.1182/blood-2025-5501

Published: 2025

Journal Articles

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Emeline Chong, Megan Jones, Guido Ghilardi, Luca Paruzzo, Sunita Dwivedy Nasta, Stefan Barta, Jakub Svoboda, Elise Chong, Jordan Carter, Colin Thomas, Michael Cook, Emily Tomasulo, Marco Ruella, Daniel Landsburg, Stephen Schuster

Blood (2025) 146 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2025-3728

Published: 2025

Journal Articles

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

Blood (2025) 146 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2025-1952

Published: 2025

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Adam Waxman, Adam D. Cohen, Dan T. Vogl, Shivani Kapur, Eugenio Fardella, Alberto Carturan, Luke Maillie, Sofia Kaparis, Jalpa A. Doshi, Alfred L. Garfall, Edward A. Stadtmauer, Carmen E Guerra, Sandra Susanibar-Adaniya, Marco Ruella

Blood (2024) 144 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2024-206544

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the “STEM” (Sequential T Cell-Engagement for Myeloma) trial

Trends in muscle and fat metrics and their association with outcomes following CAR T-cell therapy in older adults with non Hodgkin lymphoma.

Humanized PDX models reveal Lymphoma–Host interactions and enhanced T-cell therapies via epigenetic modulation

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Rebuilding immunity: Kinetics and clinical impact of immune reconstitution after CAR T-cell therapy in multiple myeloma

Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies

Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-BCMA CART Therapy for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only